Publication | Open Access

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Hematological MalignancyOncologyDexamethasone Versus BortezomibHematologyMyeloid NeoplasiaPharmacotherapyMedicineRadiation OncologyPhase 3Refractory Multiple MyelomaHealth Sciences